Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Non-Current Deffered Revenue (2024 - 2025)

Xilio Therapeutics' Non-Current Deffered Revenue history spans 2 years, with the latest figure at $25.5 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue rose 203.58% year-over-year to $25.5 million; the TTM value through Sep 2025 reached $25.5 million, up 203.58%, while the annual FY2024 figure was $19.3 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $25.5 million at Xilio Therapeutics, down from $28.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $38.7 million in Q1 2025 and bottomed at $8.4 million in Q3 2024.